Apellis Pharmaceuticals (NASDAQ:APLS) Releases Earnings Results, Misses Expectations By $0.14 EPS

Apellis Pharmaceuticals (NASDAQ:APLS) issued its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14), Briefing.com reports. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. During the same period in the prior year, the business posted ($1.17) earnings per share. The company’s quarterly revenue was up 78.3% compared to the same quarter last year.

Apellis Pharmaceuticals Trading Up 0.9 %

NASDAQ APLS traded up $0.25 during trading on Wednesday, hitting $28.33. The stock had a trading volume of 1,508,813 shares, compared to its average volume of 1,769,949. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. The company has a market capitalization of $3.45 billion, a PE ratio of -10.17 and a beta of 0.87. The firm has a 50 day moving average price of $31.58 and a 200 day moving average price of $37.26. Apellis Pharmaceuticals has a twelve month low of $24.34 and a twelve month high of $73.80.

Analyst Ratings Changes

Several analysts recently commented on the company. Piper Sandler dropped their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research report on Wednesday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $25.00 target price on shares of Apellis Pharmaceuticals in a report on Monday. Mizuho decreased their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. Needham & Company LLC dropped their price objective on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group decreased their target price on shares of Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday. Six investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.76.

Insider Transactions at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now owns 100,000 shares in the company, valued at $3,623,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).